Korro Bio (KRRO) announced the appointment of Loic Vincent, Ph.D., as the Company’s Chief Scientific Officer. Prior to joining Korro, Dr. Vincent served as Chief Scientific Officer at Affini-T Therapeutics leading efforts to advance next-generation therapies.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRRO:
- Korro Bio CFO Returns from Medical Leave
- Korro Bio Reports 2024 Financial Results and Progress
- Korro Bio price target lowered to $95 from $105 at RBC Capital
- Korro Bio’s Promising Growth: Buy Rating Backed by Positive KRRO-110 Trial Progress and Market Opportunities
- Korro Bio reports FY24 EPS ($9.37), consensus ($9.73)